Teva Pharmaceutical Industries Ltd. $TEVA Holdings Boosted by Public Sector Pension Investment Board

Teva Pharmaceutical Industries logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Public Sector Pension Investment Board increased its Teva stake by 85.1% in the third quarter, adding 570,100 shares to hold about 1.24 million shares valued at $50.9 million. Institutional investors overall own 54.05% of the company.
  • Teva reported quarterly EPS of $0.86, beating the $0.72 consensus, and revenue of $4.39 billion, above expectations; revenue was down 1.9% year over year.
  • Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $48.43. Insiders sold 715,945 shares worth about $29.1 million over the past three months.
  • MarketBeat previews top five stocks to own in December.

Public Sector Pension Investment Board increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 85.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,239,667 shares of the company's stock after purchasing an additional 570,100 shares during the quarter. Public Sector Pension Investment Board owned 0.11% of Teva Pharmaceutical Industries worth $50,913,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in TEVA. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Teva Pharmaceutical Industries by 1.3% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company's stock valued at $1,561,120,000 after acquiring an additional 500,000 shares during the period. Wellington Management Group LLP grew its stake in shares of Teva Pharmaceutical Industries by 5.8% during the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company's stock valued at $259,899,000 after purchasing an additional 419,329 shares during the period. Janus Henderson Group PLC grew its stake in shares of Teva Pharmaceutical Industries by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company's stock valued at $145,076,000 after purchasing an additional 72,880 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Teva Pharmaceutical Industries by 128.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company's stock valued at $103,538,000 after purchasing an additional 1,716,315 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Teva Pharmaceutical Industries by 2.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,864,594 shares of the company's stock valued at $86,240,000 after purchasing an additional 73,410 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 367,600 shares of the company's stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Richard D. Francis sold 250,000 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total value of $10,560,000.00. Following the completion of the sale, the chief executive officer owned 927,529 shares in the company, valued at approximately $39,178,824.96. The trade was a 21.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 715,945 shares of company stock valued at $29,061,351. Insiders own 0.54% of the company's stock.

Teva Pharmaceutical Industries News Summary

Investors following TEVA have been watching these news items:

  • Neutral Sentiment: Teva said R&D head and Chief Medical Officer Eric Hughes will leave for an outside role. David Gardiner will lead the transition while the company searches for a successor; management said its strategy, priorities and expectations are unchanged, including its ambition to reach $6–7 billion in innovative-medicine revenue by 2030. R&D leadership transition
  • Neutral Sentiment: Teva reportedly reached a settlement in a states’ generic-drug price-fixing lawsuit. A settlement could reduce ongoing legal uncertainty, but the report provided here does not specify its financial terms or potential impact. States’ generic drug price-fixing settlement
  • Negative Sentiment: Hughes’s departure removes a senior leader responsible for global R&D and medical affairs, creating some execution and succession risk while Teva works to fill the role. Teva R&D leadership announcement

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. TD Cowen increased their price target on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a "buy" rating in a research report on Wednesday, November 4th. Argus upped their price objective on Teva Pharmaceutical Industries from $42.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday. Oppenheimer raised their target price on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an "outperform" rating in a report on Friday, October 9th. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday, October 12th. Finally, Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an "overweight" rating in a report on Thursday, November 12th. Fourteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and an average target price of $48.43.

View Our Latest Analysis on TEVA

Teva Pharmaceutical Industries Trading Down 1.0%

Shares of TEVA stock opened at $42.19 on Thursday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $24.01 and a 12-month high of $44.57. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. The stock's 50-day moving average price is $40.51 and its 200-day moving average price is $35.21. The stock has a market capitalization of $49.16 billion, a price-to-earnings ratio of 98.11, a price-to-earnings-growth ratio of 3.69 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.14. The business had revenue of $4.39 billion for the quarter, compared to analysts' expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.78 EPS. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

(Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Recommended Stories

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?

Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines